13F Holdings
中文EN

TELA TELA Bio, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1561921 · Fiscal year ends 12/31

Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY13.5%
TTM net income YoY8.3%
TTM EPS YoY41.5%
Revenue 3-yr CAGR21.5%
Net income 3-yr CAGR—

Margins

Gross margin67.3%
Operating margin-41.8%
Net margin-49.3%
FCF margin-37.4%
EBITDA margin-41.1%

Returns

ROE-616.6%
ROA-54.2%
ROIC (approx.)-192.9%
Asset turnover1.10x

Leverage & solvency

Liabilities / assets107.4%
Debt / equity—
Current ratio3.61x
Interest coverage-5.56x

Cash quality & payout

Operating cash flow / net income0.74x
Accruals ratio-13.8%
Payout ratio—
Capex / revenue0.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$80.28M$69.30M$58.45M$41.42M$29.46M
Cost of revenue$25.55M$22.43M$17.96M$13.57M$10.35M
Gross profit$54.34M$46.49M$40.11M$27.04M$18.81M
R&D expense$9.22M$8.81M$9.62M$8.94M$6.74M
SG&A expense$15.69M$14.72M$14.89M$13.86M$12.46M
Operating income-$33.76M-$34.12M-$44.08M-$39.01M-$29.45M
Interest expense$5.25M$5.29M$5.22M$4.05M$3.60M
Pretax income-$38.60M-$37.98M-$46.66M-$44.30M—
Income tax$230,000-$144,000———
Net income-$38.83M-$37.84M-$46.66M-$44.30M-$33.28M
EBITDA-$33.12M-$33.48M-$43.65M-$38.62M-$29.22M
EPS (basic)-0.83-1.33-2.04-2.72-2.30
EPS (diluted)-0.83-1.33-2.04-2.72-2.30
Weighted avg. shares (diluted)46.95M28.53M22.87M16.27M14.47M
Balance sheet
Cash & equivalents$50.84M$52.94M$46.99M$42.02M$43.93M
Receivables$10.35M$10.10M$9.74M$6.62M$4.23M
Inventory$11.02M$12.78M$13.16M$11.79M$7.66M
Current assets$75.58M$78.07M$71.73M$62.45M$59.05M
PP&E, net$2.23M$2.34M$1.98M$1.68M$1.19M
Intangibles$1.36M$1.74M$2.12M$2.50M$2.30M
Total assets$81.42M$86.57M$78.05M$67.86M$62.54M
Current liabilities$17.98M$15.60M$16.97M$12.40M$10.57M
Long-term debt$55.65M$41.12M$40.52M$39.92M$31.49M
Total debt$55.65M$41.12M$40.52M$39.92M$31.49M
Total liabilities$75.11M$58.11M$59.17M$53.55M$42.45M
Shareholders' equity$6.31M$28.46M$18.88M$14.30M$20.10M
Net debt$4.81M-$11.81M-$6.48M-$2.10M-$12.44M
Shares outstanding44.54M39.40M24.49M19.17M14.53M
Cash flow statement
Operating cash flow-$28.22M-$41.59M-$40.86M-$40.75M-$30.43M
Capital expenditure$448,000$989,000$611,000$872,000$627,000
Free cash flow-$28.67M-$42.58M-$41.47M-$41.62M-$31.06M
Investing cash flow$846,000$4.45M-$599,000-$1.87M-$627,000
Financing cash flow$25.75M$43.06M$46.27M$40.85M$585,000
Depreciation & amortization$630,000$632,000$428,000$383,000$231,000
Stock-based compensation$3.80M$4.36M$5.03M$3.99M$3.66M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.